The canonical NET-selective TCA; useful as a noradrenergic reference probe but essentially exhausted as a research frontier
Look, desipramine is about as established as it gets in the TCA class. FDA-approved in 1964, it’s been the reference standard for NET-selective tricyclic pharmacology for sixty years. That dual status, canonical probe on one hand and dated workhorse on the other, is exactly what drives the score here.
The NET selectivity is real and it matters. A Ki of roughly 0.83 nM at NET versus 17 nM at SERT gives you a selectivity ratio around 20-fold, which is genuinely useful if you’re trying to dissect noradrenergic from serotonergic contributions in a mixed-reuptake experiment. Compared to imipramine, the parent compound, desipramine sheds meaningful muscarinic (M1 Ki around 200 nM) and H1 load while keeping the NET hit clean. For any investigator running catecholamine reuptake assays, building pharmacological controls, or studying NE dynamics in pain or ADHD-relevant circuits, its position as the canonical NET-selective TCA is hard to displace within that specific context. Thats the bench case for having it in the library.
But thats also where the excitement ends. The mechanism, NET reuptake inhibition, has been understood for sixty years. The binding kinetics are fully characterized, the downstream noradrenergic effects are mapped, and the CYP2D6/CYP2E1 metabolism profile is textbook. What we dont like is that atomoxetine and reboxetine both exist now, offering higher NET selectivity without the TCA off-target load. For pure noradrenergic questions, those compounds have largely superseded desipramine except in historical comparisons or when the TCA scaffold itself is under study.
The evidence base is enormous. Multiple phase 3 trials, decades of replicated clinical data, strong meta-analytic signal for MDD. Translational signal is unambiguous in the sense that it works in people and that fact is exhaustively documented. But from a research novelty standpoint, a large evidence base on a 60-year-old compound means less remaining question to answer. There’s no frontier in the depression indication, the neuropathic pain angle is mature, and the ADHD off-label use lives in the shadow of better-characterized and more selective tools.
We think desipramine earns its place in the library as a reference compound and nothing more. Investigators comparing noradrenergic agents, running assay controls, or building pharmacological models of NE reuptake will want it on the shelf. For anything asking a genuinely new question about human biology, the novelty and mechanism scores drag the overall to where it belongs: a well-characterized, historically important, presently limited research tool.